stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) P/B ratio
As of 5 November 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a P/B ratio of 3.3×. Over the past ten years it has ranged from 1.4× (December 2022) to 16.0× (December 2019); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 3.7× | 8.33% |
| FY2024 | 3.4× | 2.74% |
| FY2023 | 3.3× | 59.31% |
| FY2022 | 2.1× | (66.33%) |
| FY2021 | 6.2× | 53.69% |
| FY2020 | 4.0× | (36.34%) |
| FY2019 | 6.3× | 22.89% |
| FY2018 | 5.1× | 128.19% |
| FY2017 | 2.3× | 6.66% |
| FY2016 | 2.1× | (47.18%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 3.3× | (8.43%) |
| Jun 2026 | 3.6× | 3.88% |
| Mar 2026 | 3.5× | (6.25%) |
| Dec 2025 | 3.7× | (7.42%) |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BHVN Biohaven Ltd. compare | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.6× |
| CLDX Celldex Therapeutics, Inc. compare | 3.1× |
| AUPH Aurinia Pharmaceuticals Inc | 3.3× |
| IMNM Immunome, Inc. compare | 3.9× |
| VERA Vera Therapeutics, Inc. compare | 5.3× |
| ADMA ADMA Biologics Inc compare | 6.7× |
| VCEL Vericel Corporation compare | 6.8× |
| PVLA Palvella Therapeutics, Inc. compare | 10.4× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement